Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about C

Abbott Laboratories (NYSE:ABT) is among the Best Brain-Computer Interface Stocks.

On June 4, Reuters reported a federal judge ‌ruled that Abbott Laboratories (NYSE:ABT) must face a proposed class-action lawsuit alleging it misled consumers by marketing PediaSure Grow & Gain drinks as "clinically proven" to help children grow.

US District Judge Paul Engelmayer said labeling featuring a giraffe and ruler-like marks could lead consumers to interpret "grow" as height gain, while "gain" implied weight. Hence, the claims will proceed, and Abbott Laboratories (NYSE:ABT) must defend.

In a 75-page decision, Engelmayer noted jurors could find the firm's commercials reinforced that message, citing an ad showing a boy comparing himself to taller peers.

The corporation said its labeling is "appropriate" and backed by evidence, maintaining PediaSure supports children's growth and development.

Plaintiff Joanne Noriega said her grandson remained short after a year of daily use but became overweight, while her lawyer James Denlea said he welcomed the ruling.

Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells healthcare products. It operates through Established Pharmac

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-must-face-153214128.html)